HDL Dysfunction During the Acute Stage of Stroke "RUSH"

Not yet recruiting

Phase N/A Results N/A

Trial Description

The study investigates the effect of plasma myeloperoxidase (MPO) concentrations on HDL dysfunction during the acute stage of ischemic and haemorrhagic strokes.

Detailed Description

MRI or CT scan are used to confirm the diagnosis of haemorrhagic, ischemic and mimick stroke.
Plasma anf HDL-MPO concentrations, as well as potent HDL dysfunction, are compared in the 3 cases.
The investigators hypothesis is that MPO concentrations and subsequent HDL dysfunction could be higher in ischemic strokes than in haemorrhagic ones. MPO could be a examined as a potent marker of early stage of ischemic stroke.
Plasma MPO levels could also be discriminant regarding the mimick strokes in patient exhibiting stroke clinical picture.

Conditions

Interventions

  • Ischemic Stroke Other
    Intervention Desc: Patients with acute stage of stroke clinical picture, with ischemic, haemorrhagic or mimick stroke diagnosed using MRI or CT scan
    ARM 1: Kind: Experimental
    Label: Ischemic stroke
    Description: Patients with ischemic stroke diagnosed by MRI or CT scan
  • Haemorrhagic stroke Other
    Intervention Desc: Patients with acute stage of stroke clinical picture, with ischemic, haemorrhagic or mimick stroke diagnosed using MRI or CT scan
    ARM 1: Kind: Experimental
    Label: Haemorrhagic stroke
    Description: Patients without haemorrhagic stroke diagnosed by MRI or CT scan

Trial Population

Adult patients with clinical picture of early stage of stroke with the first signed lasting for less than 12 hours

Outcomes

Type Measure Time Frame Safety Issue
Primary Plasma MPO concentrations Through study completion, an average of 6 hours
Secondary HDL-MPO concentrations Through study completion, an average of 6 hours

Sponsors